Lexaria Bioscience Corp (LEXX)

[NetworkNewsWire]

LXRP CEO Discusses Company’s Progress in Interview

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced that its chief executive officer, Chris Bunka, was featured in a recent interview on the Uptick Network Stock Day Radio Show. Bunka leveraged the platform to discuss Lexaria’s overall accomplishments in the past three months, as well as the company’s expectations for profitability moving forward. He notes that ongoing research and development programs could open both the NSAID and Nicotine markets to Lexaria, providing an opportunity to significantly increase corporate revenues and facilitate further expansion. “In the next 12 months you won’t even recognize Lexaria,” Bunka states in the interview. “If you look at it today and look at where we are going to be in the next 12 months… I think we are going to be an entirely different company.” The full interview is available for review at http://nnw.fm/Lq94t.

To view the full press release, visit http://nnw.fm/aD2ni

About Lexaria

Lexaria Bioscience Corp. is a biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been proven to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit http://www.LexariaEnergy.com